Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changhoon Yoo

Showing results (141-150 of 250) with videos related to

Pageof 25
Sort By:
Cancer Research and Treatment|June 20, 2024
Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal AdenocarcinomaYoo Na Lee, Min Kyu Sung, Dae Wook Hwang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 6, 2021
Implication of CD69<sup>+</sup> CD103<sup>+</sup> tissue-resident-like CD8<sup>+</sup> T cells as a potential immunotherapeutic target for cholangiocarcinomaHyung-Don Kim, Seongju Jeong, Seongyeol Park, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 6, 2021
Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinomaEo Jin Kim, Changhoon Yoo, Hyo Jeong Kang, et al.
Cancers|February 15, 2022
A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITYJwa Hoon Kim, Changhoon Yoo, Seyoung Seo, et al.
Cancer Research and Treatment|October 22, 2024
Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized TrialsJaewon Hyung, Minsu Kang, Ilhwan Kim, et al.
European Radiology|August 27, 2020
CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapyJong Keon Jang, Jae Ho Byun, Ji Hun Kang, et al.
Journal of Clinical Medicine|May 20, 2020
Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic CancerWoohyung Lee, Yejong Park, Jae Woo Kwon, et al.
JAMA Network Open|October 1, 2025
Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer: A Randomized Clinical TrialHyehyun Jeong, Changhoon Yoo, Ilhwan Kim, et al.
Oncotarget|October 21, 2016
Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab eraSeyoung Seo, Jung Yong Hong, Shinkyo Yoon, et al.
Annals of Surgical Oncology|May 7, 2026
Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 TrialChanghoon Yoo, Hyehyun Jeong, Inkeun Park, et al.
Pageof 25

Showing results (141-150 of 250) with videos related to

Sort By:
Pageof 25
Cancer Research and Treatment|June 20, 2024
Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal AdenocarcinomaYoo Na Lee, Min Kyu Sung, Dae Wook Hwang, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 6, 2021
Implication of CD69<sup>+</sup> CD103<sup>+</sup> tissue-resident-like CD8<sup>+</sup> T cells as a potential immunotherapeutic target for cholangiocarcinomaHyung-Don Kim, Seongju Jeong, Seongyeol Park, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 6, 2021
Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinomaEo Jin Kim, Changhoon Yoo, Hyo Jeong Kang, et al.
Cancers|February 15, 2022
A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITYJwa Hoon Kim, Changhoon Yoo, Seyoung Seo, et al.
Cancer Research and Treatment|October 22, 2024
Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized TrialsJaewon Hyung, Minsu Kang, Ilhwan Kim, et al.
European Radiology|August 27, 2020
CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapyJong Keon Jang, Jae Ho Byun, Ji Hun Kang, et al.
Journal of Clinical Medicine|May 20, 2020
Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic CancerWoohyung Lee, Yejong Park, Jae Woo Kwon, et al.
JAMA Network Open|October 1, 2025
Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer: A Randomized Clinical TrialHyehyun Jeong, Changhoon Yoo, Ilhwan Kim, et al.
Oncotarget|October 21, 2016
Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab eraSeyoung Seo, Jung Yong Hong, Shinkyo Yoon, et al.
Annals of Surgical Oncology|May 7, 2026
Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 TrialChanghoon Yoo, Hyehyun Jeong, Inkeun Park, et al.
Pageof 25